Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11100271 | 0.81 | HRH1 (0.49) | NPC1RAB9ACYP2A6CXCR4HRH1 | |
| SCHEMBL11319871 | 0.81 | NPC1 (0.34) | NPC1RAB9AALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4625922 | 0.81 | TDP1 (0.49) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL28676139 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL28667999 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL9143648 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL29467768 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL1469935 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA | |
| Bromide SCHEMBL11605798 | 0.80 | HRH1 (0.47) | NPC1RAB9ACYP2A6CXCR4HRH1 | |
| SCHEMBL28680286 | 0.80 | TDP1 (0.47) | NPC1RAB9AL3MBTL1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101761-B2 | (E)-N-{3-[1-(8-fluoro-11H-10-OXA-1-AZA-dibenzo [A,D] cyclohepten-5ylidene)-propyl]-phenyl}-methanesulfonamide as glucocorticoid receptor modulator for the treatment of rheumatoid arthritis | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2231676-B1 | (E)-N-{3-[1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO-[A,D]-CYCLOHEPTEN-5-YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | LILLY CO ELI (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100280062-A1 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ELI LILLY AND COMPANY (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2231676-A1 | (E)-N-{3-[1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO[A,D]-CYCL0HEPTEN-5YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID | Eli Lilly & Company (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009089312-A1 | (E)-N-{3- [1-(8-FLUORO-11H-10-OXA-1-AZA-DIBENZO [A,D] CYCL0HEPTEN-5YLIDENE)-PROPYL]-PHENYL }-METHYNSULFON AMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID | ELI LILLY AND COMPANY (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280062-A1 | (E)-N--METHANESULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | NR3C1, NR3C2, MC2R | NPC1 1328/4885RAB9A 872/4885ALDH1A1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.